menu
    • menu
    [{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"90-Y Resin","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"6","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sirtex Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Tavokinogene Telseplasmid","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase II","graph3":"Sirtex Medical","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"Tavokinogene Telseplasmid","moa":"||Interleukine 12 (IL-12)","graph1":"Oncology","graph2":"Phase II","graph3":"Sirtex Medical","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Oncology","graph2":"Phase II","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sirtex Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Bright Research Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"99m-Tc Macro Albumin Aggregate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase IV","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Bright Research Partners","highestDevelopmentStatusID":"11","companyTruncated":"Sirtex Medical \/ Bright Research Partners"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MAA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sirtex Medical \/ Sirtex Medical"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Sirtex Medical \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirtex Medical \/ Sirtex Medical","highestDevelopmentStatusID":"6","companyTruncated":"Sirtex Medical \/ Sirtex Medical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sirtex Medical

    Menu

    Sirtex Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Macro Albumin Aggregate

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Bright Research Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

                            Details : 99m-Tc Macro Albumin Aggregate is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 08, 2023

                            Lead Product(s) : 99m-Tc Macro Albumin Aggregate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Bright Research Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microsp...

                            Details : SIR-Spheres Y-90 resin microspheres is the first therapeutic radiopharmaceutical approved by the NMPA based on clinical trial data, for the treatment of patients with colorectal cancer liver metastases.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 09, 2022

                            Lead Product(s) : Yttrium Radioisotopes

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 90-Y Resin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Co...

                            Details : 90-Y Resin is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasm Metastasis.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : 90-Y Resin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : OncoSec Immunotherapies

                            Deal Size : $30.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

                            Details : Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.

                            Product Name : Tavo

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : OncoSec Immunotherapies

                            Deal Size : $30.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : OncoSec Immunotherapies

                            Deal Size : $30.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sirtex Medical closes Strategic Transaction with OncoSec Medical

                            Details : Sirtex will support and assist OncoSec with pre-marketing activities for TAVO™ and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products.

                            Product Name : Tavo

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $30.0 million

                            February 10, 2020

                            Lead Product(s) : Tavokinogene Telseplasmid,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : OncoSec Immunotherapies

                            Deal Size : $30.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With...

                            Details : Cisplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Cholangiocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 21, 2016

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Roger Williams Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

                            Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Liver Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 15, 2015

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Roger Williams Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Regorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Met...

                            Details : Regorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2014

                            Lead Product(s) : Regorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal C...

                            Details : Fluorouracil is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 06, 2012

                            Lead Product(s) : Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sirtex Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAA

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Magdeburg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy

                            Details : MAA is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 23, 2010

                            Lead Product(s) : MAA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Magdeburg

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth